in Caucasians, people who live in Central Europe (1.84%) and Western Europe (1.92%), and people from North America (1.50%) [6]. The authors [1,4] report that psoriasis occurs with the same frequency in both sexes and its first symptoms can manifest at any age, but two peaks of incidence are noted. In men, this is 30-39 years or 60-69 years, while in women, psoriasis can appear at 18-29 years or 50-59 years. The average age of its onset is 33 years [5]. In the pediatric population, on the other hand, the authors [4] indicate that psoriasis is not common in this age group, as the prevalence is 0.13% in children aged 0-2 years to 0.67% in children aged 14-18 years. The authors point out that the quality of life of patients with psoriasis is significantly impaired, which is associated not only with the presence of increased skin symptoms such as desquamation and pruritus, but also with significant psychosocial consequences, including social stigmatization and increased risk of psychiatric disorders. As studies [3,5] show, compared to the general population, patients with psoriasis are significantly more likely to be depressed (up to 20%) without excluding thoughts and attempts related to suicide. Nowadays, psoriasis is not treated only as an inflammatory disease, but as a condition whose effects are systemic and increase the risk of coexisting metabolic syndrome, psoriatic arthritis, or depression [2,5]. Both genetic, immunological and environmental factors such as streptococcal infection, stress, smoking, obesity or alcohol consumption are involved in its etiopathogenesis [1]. Recent immunological studies conducted on the pathogenesis of psoriasis have identified interleukin-17 (IL-17) and interleukin-23 (IL-23) as a major pathogenic factor, thereby highlighting the importance of the immune system in the course of psoriasis [5]. The interaction of IL-23 and IL-17 influences inflammation, which increases during the active phase of the disease, which triggers the body's pro-inflammatory response, resulting in the activation and proliferation of keratinocytes [7]. The authors [8] identify IL-23 as the main cytokine in psoriatic disease. In addition to interleukins 17 and 23, other pro-inflammatory cytokines also play an important role in the etiopathogenesis of psoriasis, such as tumor necrosis factor alpha (TNF-\(\alpha\)), interleukin 12 (IL-12), interleukin 36 (IL-36), and interleukin 6 (IL-6), which are important therapeutic targets in current biological therapies [5,7,8]. Targeted biological action on specific cytokines has revolutionized the treatment of psoriasis, surpassing traditional immunosuppressive therapies in terms of efficacy and safety. With this approach, a new standard in therapy has been achieved, based on precise immunomodulation [8]. The authors [2,5,7] point out that psoriasis is currently an incurable disease. The treatment of psoriasis is directed in two ways: through the use of topical preparations and the use of broad-spectrum systemic treatment. Topical treatment is a fundamental and essential part of psoriasis therapy, regardless of the severity or stage of the disease. Although it is primarily recommended for patients with mild or limited psoriasis, it also plays an important role in more severe cases and during systemic or biological treatment [9]. It involves the use of exfoliating drugs in the first stages of treatment, followed by anti-inflammatory and keratosis-regulating drugs. Systemic treatment, on the other hand, should be used for psoriasis of moderate to severe severity [9]. The authors [9,10] emphasize that systemic corticosteroids should not be used in the treatment of psoriasis because, despite their anti-inflammatory effect, they are associated with a high risk of relapse and exacerbation of psoriatic lesions when the dose is reduced or discontinued. Topical therapies, phototherapy, oral systemic therapies, and biologics are the standard of care for psoriasis [11]. According to the authors [9], an important factor in the treatment of psoriatic skin is skin care.